NCT00671619

Study of ESBA105 Eye Drops in Healthy Subjects

A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: ESBATech AG · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers. To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.

Detailed description

ESBA105 is an anti TNF single chain antibody fragment

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ESBA105	eye drops

Timeline

• Start date: 2008-04-01
• Primary completion: 2008-07-01
• Completion: 2008-08-01
• First posted: 2008-05-05
• Last updated: 2008-08-25

Locations

1 site across 1 country: Switzerland